Compare Levi Strauss & Co. (LEVI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Medpace Holdings Inc — how do they compare? Levi Strauss & Co. trades at $22.54 (market cap $8.75B), while Medpace Holdings Inc trades at $601.96 (market cap $16.90B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 2.81% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| LEVI | MEDP | |
|---|---|---|
Market Cap | $8.75B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $25.53 | $620.59 |
52-Week Low | $17.92 | $393.42 |
Enterprise Value | $10.07B | $16.52B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $22.57, down 4.32% amid a recent cybersecurity breach disclosure. The stock maintains strong fundamentals with a 9.66% net margin and 29.31% ROE, supported by three consecutive quarterly earnings beats. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions. Analyst consensus remains strongly bullish with a $27.88 price target representing 23.5% upside potential.
Despite near-term cybersecurity concerns, Levi's demonstrates robust DTC growth and digital transformation success. The company's raised 2026 outlook and dividend increase signal confidence, though execution risks and tariff pressures warrant monitoring. Current valuation at 16.24 P/E offers reasonable entry for long-term investors seeking exposure to the iconic brand's turnaround story.
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
